The U.S. Food and Drug Administration (FDA) issued a safety communication explaining the increased risk of heart failure in patients taking diabetes medications containing saxagliptin and alogliptin. In response to the results of two large clinical trials, the FDA has added new warnings to the drug labels of medication containing saxagliptin and alogliptin. Health care professionals should consider discontinuing such medications if patients develop heart failure.

Read the FDA announcement.

Keywords: Adamantane, Diabetes Mellitus, Dipeptides, Heart Failure, Piperidines, United States Food and Drug Administration, Uracil

< Back to Listings